Compare
BeyondSpring Inc. vs Abbott Laboratories vs Bristol Myers Squibb Co vs TherapeuticsMD, Inc.
| Latest fiscal year | BeyondSpring Inc. BYSI | Abbott Laboratories ABT | Bristol Myers Squibb Co BMY | TherapeuticsMD, Inc. TXMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $0 | $44.33B | $48.19B | $3.02M |
| Revenue growth (YoY) | n/a | +5.7% | -0.2% | +71.6% |
| Gross margin | n/a | 56.4% (computed) | n/a | n/a |
| Operating margin | n/a | 18.2% | n/a | -145.3% |
| Net margin | n/a | 14.7% | 14.6% | -18.8% |
| Net income | -$1.01M | $6.52B | $7.05B | -$569.0K |
| EPS (Diluted) | n/a | $3.72 | $3.46 | -$0.05 |
| Operating cash flow | -$19.77M | $9.57B | $14.16B | $2.45M |
| Free cash flow | -$19.82M | $7.39B | $12.85B | n/a |
| Cash & equivalents | $7.79M | $8.52B | $10.21B | n/a |
| Total assets | $25.93M | $86.71B | $90.04B | $37.66M |
| Total liabilities | $49.92M | n/a | $71.53B | $10.78M |
| Shareholders' equity | -$23.99M | $52.13B | $18.47B | $26.88M |
| Return on year-end equity | n/a | 12.5% | 38.2% | -2.1% |
| Shares outstanding | n/a | n/a | n/a | 11.57M |
Revenue, most recent five fiscal years
| Fiscal year | BeyondSpring Inc. | Abbott Laboratories | Bristol Myers Squibb Co | TherapeuticsMD, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2025-12-31 | $44.33B Ended 2025-12-31 | $48.19B Ended 2025-12-31 | $3.02M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | $41.95B Ended 2024-12-31 | $48.30B Ended 2024-12-31 | $1.76M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $40.11B Ended 2023-12-31 | $45.01B Ended 2023-12-31 | $1.30M Ended 2023-12-31 |
| 3 years earlier | $1.35M Ended 2022-12-31 | $43.65B Ended 2022-12-31 | $46.16B Ended 2022-12-31 | $69.96M Ended 2022-12-31 |
| 4 years earlier | $1.35M Ended 2021-12-31 | $43.08B Ended 2021-12-31 | $46.38B Ended 2021-12-31 | $2.57M Ended 2021-12-31 |